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Protein kinase CK2 (casein kinase 2) is a eukaryotic serine/threonine protein kinase with multiple sub-
strates and roles in diverse cellular processes, including differentiation, proliferation, and translation. The
mammalian holoenzyme consists of two catalytic alpha or alpha subunits and two regulatory beta subunits.
We report the identification and characterization of a Plasmodium falciparum CK2 orthologue, PfCK2, and
two PfCK2 orthologues, PfCK21 and PfCK22. Recombinant PfCK2 possesses protein kinase activity,
exhibits similar substrate and cosubstrate preferences to those of CK2 subunits from other organisms, and
interacts with both of the PfCK2 subunits in vitro. Gene disruption experiments show that the presence of
PfCK2 is crucial to asexual blood stage parasites and thereby validate the enzyme as a possible drug target.
PfCK2 is amenable to inhibitor screening, and we report differential susceptibility between the human and
P. falciparum CK2 enzymes to a small molecule inhibitor. Taken together, our data identify PfCK2 as a
potential target for antimalarial chemotherapeutic intervention.
Malaria, caused by infection with intracellular protozoan
parasites of the genus Plasmodium, is responsible for 300 mil-
lion to 600 million clinical cases annually (49), resulting in the
deaths of up to 3 million people every year (9, 10). The need
for novel intervention strategies is rendered more acute by the
rise of resistance of the parasites (especially Plasmodium fal-
ciparum, the causative agent of the most virulent form of the
disease) to most available drugs. There is a clear need for
further research aimed at identifying novel drug targets (43).
The parasite life cycle is complex, with a succession of pro-
liferation and differentiation events, in the regulation of which
protein phosphorylation is likely to play crucial roles. Revers-
ible phosphorylation of proteins is a major regulatory mecha-
nism in most cellular processes, and approximately 30% of all
eukaryotic cellular proteins carry a phosphate group. Deregu-
lation of protein phosphorylation underlies various patholo-
gies, including cancers, and protein kinases are considered
promising drug targets, comprising as much as 30% of all
protein targets under investigation (13). The divergences be-
tween human and plasmodial protein kinases suggest that spe-
cific inhibition of the latter is an achievable goal (14, 15).
Protein kinase CK2, formerly known as casein kinase II, is a
serine/threonine protein kinase ubiquitously expressed in eu-
karyotes. It has over 300 cellular substrates catalogued to date
(34). Consistent with its multiple substrates, the enzyme plays
a crucial role in many cellular processes, including differenti-
ation, proliferation, survival, translation, apoptosis, cell cycle
progression, and cellular responses to stress and DNA damage
(1, 38); mammalian CK2 has even been found to act as an
exokinase, phosphorylating several extracellular proteins (44,
55). CK2 is essential to viability in yeasts and slime molds (24,
37). The human CK2 holoenzyme consists of two catalytic
alpha or alpha subunits and two regulatory beta subunits, and
recent evidence indicates that the beta subunits interact with
several protein kinases in addition to CK2 (reviewed in ref-
erence 6), pointing to a likely role in the integration of numer-
ous signaling pathways. The human genome encodes three
CK2 subunits and a single version of the beta subunit. In-
creasing evidence shows that CK2 is an attractive target for
antineoplastic and antiviral drugs (46).
The genome of the P. falciparum strain 3D7 (18) has been
fully sequenced, allowing the discovery of the entire comple-
ment of plasmodial protein kinases by analysis of the set of
predicted peptides (3, 57). A putative CK2 orthologue and
two predicted CK2 subunits were identified in these analyses.
Here we present the biochemical characterization of the
PfCK2 and both PfCK2 orthologues and demonstrate by
using a reverse genetics approach that the catalytic subunit is
essential for completion of the erythrocytic asexual cycle of the
parasite.
MATERIALS AND METHODS
Expression and purification of the three PfCK2 subunits. Oligonucleotides
were designed to amplify the PfCK2 open reading frame (ORF) from P.
falciparum (clone 3D7A) cDNA. The forward (5-GGGGGGATCCATGTCGG
TTAGCTCAATTAATAAA-3) and reverse (5-GGGGGTCGACTTATGATT
CCTCACGGTCTTCTC-3) primers carried BamHI and SalI sites, respectively
(underlined). Oligonucleotides were also designed to amplify the PfCK21 and
PfCK22 ORFs from P. falciparum (clone 3D7A) cDNA. The PfCK21 forward
(5-GGGGAGATCTATGGAAAATAGTGATTCGAATAAAGAC-3) and re-
verse (5-GGGGGTCGACTTACGTTTCAGAAATTTGTAGTTCTTCC-3)
primers carried BglII and SalI sites, respectively (underlined). The PfCK22
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sequence has a long N-terminal extension. Oligonucleotides were designed to
amplify the PfCK22 sequence, lacking the N-terminal extension, from P. fal-
ciparum (clone 3D7A) cDNA. The forward (5-GGGGGGATCCATGGAAGC
AACAGTGTCTTGGATTG-3) and reverse (5-GGGGGTCGACTCATTGA
CACTCTTCAGAGGATTCCG-3) primers carried BamHI and SalI sites,
respectively (underlined). The short version of PfCK22, lacking the N-terminal
extension, was named shPfCK22. Catalytically inactive (“kinase dead”) PfCK2
was obtained by site-directed mutagenesis (K72M) of pGEX-PfCK2 by overlap
extension PCR (23). All cloning primers are provided in Table S1 in the sup-
plemental material. All PCR products were verified by sequencing in the vector
pGEM-T Easy (Promega) and then subcloned into the plasmid pGEX-4T3 (GE
Healthcare) to generate N-terminal glutathione S-transferase (GST) fusions.
The shPfCK22 sequence was also inserted between the BamHI and NotI sites
of the plasmid pQE-30 for expression with an N-terminal His6 tag. A pET29
vector containing P. falciparum CK2 in frame with a C-terminal His6 tag
sequence was a kind gift from D. Chakrabarti. The pGEX4T3 constructs were
expressed in Escherichia coli BL21 Gold cells, SG13009 cells were used for
expression from the pQE30 plasmid, and the pET29 construct was expressed in
E. coli BL21(DE3) cells for 20 h at 20°C with 0.1 mM isopropyl--D-thiogalac-
topyranoside (IPTG). GST-tagged proteins were purified on glutathione-agarose
beads (Sigma), and His-tagged proteins were purified on Ni2-agarose beads
(Qiagen), following the manufacturer’s recommendations.
Construction of the knockout (KO) plasmid pCAM-BSD-KOPfCK2. A frag-
ment from the PfCK2 ORF was amplified by PCR and inserted between the
BamHI and NotI sites of the pCAM-BSD plasmid (47), which contains the
Aspergillus terreus blasticidin-S-deaminase gene, whose gene product confers
resistance to the drug blasticidin. Cloning primers are listed in Table S1 in the
supplemental material.
Construction of the complementation plasmid pCHD-PfCK2a. A plasmid for
in vivo episomal expression of PfCK2 subunits was constructed as follows: the
full-length PfCK2 coding sequence was first inserted between the BglII and
NotI sites of the plasmid pHGB (51) and then transferred into the plasmid
pCHD-1/2 (51) by a Gateway LR clonase reaction according to the manufactur-
er’s instructions (Invitrogen). The plasmid pCHD-1/2 includes a cassette encod-
ing human dihydrofolate reductase, conferring resistance to the antifolate drug
WR99210. Parasites that were transfected with both a KO plasmid and a comple-
mentation plasmid were cultured under double-drug selection (see below).
3-Tagging plasmid. The 3 end of the PfCK2 coding sequence (538 bp,
omitting the stop codon) was amplified by PCR using primers incorporating PstI
and BamHI restriction sites and inserted between the PstI and BamHI sites of
the pCAM-BSD-hemagglutinin (HA) plasmid (42).
Kinase assays. Standard kinase reactions (30 l) occurred in kinase buffer (20
mM Tris-HCl [pH 7.5], 20 mM MgCl2, 2 mM MnCl2, and 10 M ATP) con-
taining 0.075 MBq [-32P]ATP (370 MBq/ml; GE Healthcare), 1 g of recom-
binant kinase, and 5 g of substrate. Reactions were carried out at 30°C for 30
min and terminated by the addition of Laemmli buffer. Samples were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The
gels were dried and exposed for autoradiography.
Kinase assays were also analyzed by the phosphocellulose method (20). A final
assay volume of 18 l contained 36 ng of PfCK2, 167 mM of peptide substrate,
50 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 25 M ATP, 40 to 150 mM NaCl, and
0.037 MBq [-32P]ATP (220 TBq/mmol; GE Healthcare). Reactions took place
for 10 min at room temperature and were terminated by the addition of 60 l of
4% trichloroacetic acid. Reaction mixtures were centrifuged at 10,000  g for 15
min, and then 60 l of supernatant was spotted onto 4- by 4-cm Whatman P81
phosphocellulose paper squares. The squares were washed three times for 15 min
in 0.5% orthophosphate, and then the amount of radiolabel incorporated into
the peptide substrate was quantified by scintillation counting. Three peptides
substrates were used in this study, the NEB peptide p6012 (RRRADDSDDD
DD), the custom peptide (RRREDEESDDEE), obtained from NeoMPS, and
the eIF2-derived peptide (MSGDEMIFDPTMSKKKKKKKKP) (40, 45), ob-
tained from GeneCust (Evry, France).
The Kms of PfCK2 for ATP and GTP were determined by performing kinase
assays with ATP concentrations of 100 M, 25 M, 6.25 M, and 1.5625 M.
Reactions were carried out in triplicate. The [-32P]ATP/GTP was added to the
unlabeled ATP/GTP and diluted serially to ensure a constant ratio of labeled-
to-unlabeled ATP/GTP. The NEB peptide RRADDSDDDDD (100 M) was
used as the substrate. The Kms of PfCK2 for ATP in the presence or absence
of PfCK2 were determined by performing kinase assays in triplicate with ATP
concentrations of 100 M, 50 M, or 25 M, with the NeoMPS peptide (100
M) as a substrate. Reaction mixtures contained 36 ng of PfCK2 alone or in
combination with 36 ng of PfCK21/shPfCK22.
Measurement of 50% inhibitory concentrations (IC50s). To test the effect of
small molecule inhibitors on PfCK2, kinase activity was measured in the pres-
ence of increasing concentrations of these molecules. Stocks of the molecules
contained dimethyl sulfoxide or ethanol as a solvent, and negative controls for
the reactions were provided by reaction mixtures containing ethanol or dimethyl
sulfoxide without the small molecule inhibitor. Kinase reactions were performed
by the phosphocellulose method as detailed above.
Interaction assay. A mixture of 5 g of each recombinant protein was incu-
bated at 4°C for 30 min in 20 mM Tris-HCl (pH 7.5), 0.2 M NaCl, 0.1% Nonidet
P40 (IGEPAL), and 10% glycerol. Glutathione-agarose beads were added to
each reaction mixture. The tubes were rotated at 4°C for 1 h; the beads were
recovered by centrifugation and washed four times in reaction buffer. Laemmli
buffer was added to the beads, which were then heated to 100°C. Samples were
separated by SDS-PAGE on 12% acrylamide gels and either stained or trans-
ferred to the membrane for Western blot analysis.
Western blot analysis. Western blotting was performed according to conven-
tional protocols. Briefly, samples were separated by SDS-PAGE on a 12%
acrylamide gel and blotted onto nitrocellulose. The membranes were blocked
according to standard methods and incubated with rabbit anti-His antibody
(1:1000; Santa Cruz Biotechnology) or subunit-specific antibodies generated in
rabbits by BioGenes (Germany) against the PfCK2-derived peptide ADVNIH
KPKEYYDY. A goat anti-rabbit secondary antibody coupled to horseradish
peroxidase was used at a ratio of 1:10,000. Antigen was visualized using the
enhanced chemiluminescence system (PerkinElmer).
Parasite culture and transfection. Cultures of the P. falciparum strain 3D7A
(54) were maintained at 37°C in RPMI 1640 medium (Gibco) supplemented with
25 mM sodium bicarbonate, 2 mM L-glutamine, 300 mM hypoxanthine, 10 g/ml
gentamicin, and AlbuMAX II (Sigma). Cultures were seeded at 5% hematocrit
and maintained at a parasitemia of 1 to 10% with daily changes of medium. The
incubator was flushed with a gas mixture containing 5% CO2.
For transfection, asexual blood stage parasites were synchronized by sorbitol
treatment (26) to obtain a majority of ring stage parasites. Forty-eight hours
later, ring stage parasites were transfected by electroporation with 100 g of
purified plasmid DNA in Cytomix buffer as described previously (16, 17, 47).
Blasticidin (2.5 g/ml) was added to the culture medium to select for trans-
formed parasites. Parasites under double selection had WR99210 (5 nM) added
to the culture medium in addition to the blasticidin. Parasites were maintained
in this supplemented medium from 2 days posttransfection.
Preparation of parasite protein extract. Parasite cultures were lysed in 0.15%
saponin. After centrifugation and washing, the parasite pellets were sonicated in
RIPA buffer (30 mM Tris, pH 8.0, 150 mM NaCl, 20 mM MgCl2, 1 mM EDTA,
0.5% Triton X-100, 1% Nonidet P40, 10 mM -glycerophosphate, 10 mM NaF,
1 mM phenylmethylsulfonyl fluoride, 10 mM benzamidine hydrochlorate hy-
drate, and Roche complete cocktail protease inhibitors). The lysates were
cleared by centrifugation (15,000 rpm for 15 min at 4°C), and the total amount
of proteins in the supernatant was measured using the Bradford assay (8).
DNA extraction and Southern blotting. Parasite cultures were lysed in 0.15%
saponin. The parasite pellets were resuspended in cold phosphate-buffered saline
and treated with proteinase K (150 g/ml) and 2% SDS at 55°C for 2 to 3 h. The
genomic DNA was extracted in phenol/chloroform/isoamyl alcohol (25:24:1) and
precipitated in ethanol and 0.3 M sodium acetate. The DNA was digested with
HindIII.
Primers used in genotype characterization. For the detection of integration of
the plasmid pCAM-BSD-KOPfCK2 into genomic DNA, the following primers
were used (see Fig. 6A for numbering and see Table S1 in the supplemental
material for the sequences): primer 1, CK2a5primeF; primer 2a, CK2aR; primer
2b, CK2a3primeR; primer 3, pCAM-BSDF; and primer 4, pCAM-BSDR.
For the detection of integration of the plasmid pCAM-BSD-HA, the following
primers were used (see Fig. 7D for numbering and see Table S1 in the supple-
mental material for the sequences): primer 1, CK2aF; primer 2, CK2a3primeR;
primer 3, pCAM-BSDF; and primer 4, pCAM-BSDR.
RESULTS
Bioinformatics. Phylogenetic analysis of P. falciparum pro-
tein kinases identified the PlasmoDB (http://plasmodb.org
/plasmo) sequence PF11_0096 as that of a CK2 orthologue
(3, 57), with 65% amino acid sequence identity to Homo sapi-
ens CK2. PF11_0096 was therefore named PfCK2. An align-
ment of PfCK2 with CK2 subunits from H. sapiens and Zea
mays (see Fig. S1 in the supplemental material) reveals that
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PfCK2 possesses all 11 of the subdomains conserved across
eukaryotic protein kinases (21, 22) and the majority of the
conserved features of CK2 subunits (2). Just downstream
from subdomain II is a putative nuclear localization signal,
Pro-Val-Lys-Lys-Lys-Lys-Ile, conserved across CK2 homo-
logues. PfCK2 also possesses three invariant residues com-
mon to CK2 family members; the ATP binding motif present in
most other protein kinases is Gly-X-Gly-X-X-Gly, whereas in
the CK2 family the motif is Gly-X-Gly-X-X-Ser (PfCK2,
Gly50-Ser55). The most highly conserved amino acid motif
specific to members of the CK2 family is Asp179-Trp-Gly181
(notation from PfCK2; most protein kinases display Asp-Phe-
Gly at this position). Likewise, Gly203-Pro-Glu205 (notation
from PfCK2) is a common feature of the family, which di-
verges from the Ala-Pro-Glu motif present in the vast majority
of other protein kinases; thus, all three CK2-specific motifs are
present in PfCK2.
Two putative CK2 subunits were identified in P. falcip-
arum (57), hereafter referred to as PfCK21 and PfCK22
(PlasmoDB identifiers PF11_0048 and PF13_0232, respectively).
BLASTP searches using the putative PfCK21/PfCK22
amino acid sequences as queries confirmed their identities as
CK2 orthologues. An alignment with the human CK2 se-
quence (HsCK2) (Fig. 1) reveals that many of the conserved
features of CK2 subunits, including the four cysteine residues
responsible for zinc finger formation (12), are present in
PfCK21 and PfCK22 (e.g., Cys117, -122, -145, and -148 for
PfCK21) (Fig. 1). The human CK2 sequence has a well-
documented CK2 phosphorylation site at the N terminus
(SSEE). PfCK22 possesses several phosphorylatable residues
in the N-terminal region that are surrounded by a number of
acidic residues, which could therefore be phosphorylated by
CK2, and a TESSEE sequence at the C terminus reminiscent
of the HsCK2 N-terminal phosphorylation site (MSSEE).
The stretch of amino acids found to be necessary for the export
of CK2 as an ectokinase (CK2 amino acids E20 to K33) (44)
are largely conserved in the PfCK2 sequences, leading to the
intriguing possibility that PfCK2 may be exported from the
parasite. The acidic stretch responsible for downregulation of
CK2 activity and association with the plasma membrane
(HsCK2 amino acids D55 to D64) (29, 32) is present in
PfCK21 (D68 to D75) and extended in PfCK22 (D207 to
E226). This insertion occurs in a region looping out from the
main protein structure (12) and is not unique; for example,
Saccharomyces cerevisiae CK2 has an insertion sequence of 30
amino acids in this location. Along with the insertion region,
PfCK22 has a highly acidic and repetitive N-terminal exten-
FIG. 2. GST-PfCK2 kinase activity. (A) Autoradiograms (left)
and Coomassie blue-stained gels (right) of kinase assays performed
with GST-PfCK2 (top) or catalytically inactive GST-K72MPfCK2
(bottom) and the following substrates: lane 1, no substrate; lane 2,
-casein; lane 3, -casein; lane 4, mixed dephosphorylated caseins;
lane 5, myelin basic protein; lane 6, histone H1; lane 7, GST-
shPfCK22; and lane 8, GST. (B) Autophosphorylation can occur by a
transreaction. Left, autoradiogram; right, Coomassie blue-stained gel.
The band observed at roughly 66 kDa is the GST-PfCK2 autophos-
phorylation band, and the band at roughly 40 kDa is the PfCK2-His
autophosphorylation band. Lane 1, GST-PfCK2; lane 2, GST-
K72MPfCK2; lane 3, PfCK2-His; and lane 4, GST-K72MPfCK2
plus PfCK2-His. Radioactive phosphate is incorporated into catalyt-
ically inactive PfCK2 (K72MPfCK2) in the presence of PfCK2-
His, indicating that autophosphorylation can occur by an intermolec-
ular reaction.
FIG. 1. Alignment of PfCK21 and PfCK22 with Homo sapiens
CK2. ClustalW alignments of the following proteins were performed:
Homo sapiens CK2 (HsCK2; AAM50092); PfCK21 (AAN35637;
PlasmoDB PF11_0048; 33% identical to HsCK2), PfCK22
(CAD52554; PlasmoDB PF13_0232; 39% identical to HsCK2). Note
the long N-terminal extension and acidic insertion sequence in
PfCK22. The sequence of shPfCK22 begins (after an artificially
introduced initiating methionine) with residue E156, underlined. The
cysteine residues thought to hold the zinc finger in place are indicated
in bold text and with arrowheads. The potential autophosphorylation
site on PfCK22 (SSEE) is indicated in bold. The export of CK2 as an
ectokinase is mediated by CK2 residues 20 to 33 (44) (boxed, along
with the equivalent residues in PfCK21 and PfCK22). The acidic
region mentioned in the text is also boxed (D107 to E133 of PfCK22).
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sion that is not found in other CK2 subunits. The N-terminal
region is at the periphery of the 3D structure of the human
CK2 peptide (12, 35) and is not a conserved part of the CK2
structure and thus may possibly function as a docking site or
region that interacts with binding partners or substrates of the
PfCK2 holoenzyme. The human CK2 is phosphorylated at
S209 in a cell cycle-dependent manner by p34cdc2 (19, 30, 33),
although the function of this phosphorylation is unknown.
Both PfCK2 subunits possess serine residues near the C ter-
minus that could be phosphorylated.
Microarray data available on PlasmoDB reveal that the
mRNAs encoding all three subunits are detectable throughout
the parasite life cycle (7, 28). Expression of the PfCK2 pro-
tein in asexual blood stage parasites was verified by Western
blot analysis (see Fig. 7F).
In vitro activity of PfCK2. Kinase activity of bacterially
expressed recombinant GST-PfCK2 was detected by an in
vitro kinase assay (Fig. 2, top). GST-PfCK2 autophosphory-
lates (the 66-kDa band present in each lane in Fig. 2 corre-
sponds to the size of the GST-tagged PfCK2 subunit) and is
capable of phosphorylating a range of exogenous substrates,
with strongest activity toward the caseins (Fig. 2, lanes 2 to 4)
and recombinant GST-tagged shPfCK22, a short version of
the PfCK22 subunit lacking the N-terminal extension (see
Materials and Methods) (Fig. 2, lane 7). There was no activity
against the GST moiety alone (Fig. 2, lane 8), indicating that
the activity in lane 7 was against the beta subunit itself and that
the autophosphorylation is against the PfCK2 subunit itself.
We did not detect any activity against the PfCK21 subunit
(data not shown). These observations are consistent with gen-
eral preferences of CK2 homologues for substrates with highly
acidic phosphoacceptor sites (11, 25, 39, 52, 56); several po-
tential such sites are present on PfCK22. Parallel assays per-
formed with an inactive PfCK2 mutant (Lys72Met; the Lys
residue is required for correct orientation of the ATP mole-
cule) were negative for kinase activity, confirming that activity
is indeed due to PfCK2 (Fig. 2, bottom). PfCK2 autophos-
phorylates by a transreaction (Fig. 2B); GST-PfCK2 and
PfCK2-His autophosphorylate (Fig. 2, lanes 1 and 3), while
GST-K72MPfCK2 does not (Fig. 2, lane 2) but is phosphor-
ylated in the presence of PfCK2-His, indicating that at least a
proportion of the autophosphorylation of PfCK2 occurs by an
intermolecular reaction.
PfCK2 shares features in common with CK2 from other
systems. A feature often cited as being characteristic of CK2
enzymes is that they have similar affinities for GTP and ATP.
PfCK2 has a Km of 16.7 M and Vmax of 6.6 nmol/min for
FIG. 3. PfCK2 kinetics. The enzyme kinetics of PfCK2 in a Line-
weaver-Burke presentation. The experiments were performed in trip-
licate, the data points represent the means, and the error bars repre-
sent three standard deviations. (A) The graph was obtained by linear
regression of the enzyme kinetic data for ATP and GTP. The inter-
cepts on the x axis give the negative reciprocal of the Km, and the
intercepts on the y axis give the reciprocal of the Vmax. (B) The graph
was obtained by linear regression of the enzyme kinetic data for the
NEB peptide RRRADDSDDDDD. The intercept on the x axis gives
the negative reciprocal of the Km.
FIG. 4. PfCK2 and HsCK2 interact in vitro. To further test the
interactions of the alpha and beta subunits, two substrates that are
phosphorylated by the CK2 holoenzyme and not by the CK2 subunit
alone were included in kinase assays with mixtures of human and P.
falciparum alpha and beta subunits. (A) Phosphorylation of the
eIF2[1-22] peptide (40, 45) by PfCK2-His or HsCK2 in the pres-
ence and absence of GST-PfCK21, GST-shPfCK22, or HsCK2 was
measured by kinase assays, and the amount of radiolabel incorporated
into the peptide was counted by scintillation. Results are shown as the
means of two experiments, with the error bars representing the stan-
dard deviations. (B) Phosphorylation of the GST-Olig2[1-177] protein
(27) by PfCK2-His (lanes 1 to 4) or HsCK2 (lanes 5 to 8) alone
(lanes 1 and 5) or in the presence of GST-PfCK21 (lanes 2 and 6),
GST-shPfCK22 (lanes 3 and 7), or HsCK2 (lanes 4 and 8). Top,
autoradiogram; bottom, corresponding Coomassie blue-stained gel of
the kinase assay.
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ATP and a Km of 34.9 M and Vmax of 2.1 nmol/min for GTP
(Fig. 3A). The enzyme displays a number of other features that
confirm it as a true member of the CK2 family: (i) PfCK2 is
able to phosphorylate the CK2 substrate peptide RRRADDS
DDDDD (NEB), with a Km of 137.5 M (Fig. 3B); (ii) CK2
enzymes are known to have a wide variety of substrates (34),
and correspondingly, PfCK2 (but not the K72M mutant pro-
tein used as a negative control) phosphorylates a number of
proteins within heat-inactivated parasite protein extract (data
not shown); (iii) the activity of PfCK2 is inhibited by the
well-established CK2-specific inhibitor TBB (3,4,5,6-tetrabro-
mobenzotriazole), with a similar IC50 curve to that of human
CK2 (IC50 for PfCK2, 2 M; IC50 for HsCK2, 1.5 M)
(see Fig. 8C); and (iv) it can be recruited by the human CK2
subunit to phosphorylate the eIF2-derived peptide (40, 45)
and the Olig2 protein (27) (Fig. 4). This is in line with the
established ability of human CK2, but not CK2 alone, to
phosphorylate the substrates used in this experiment (27, 40).
PfCK2 and the PfCK2 beta subunits interact in vitro. To
assess whether the two regulatory PfCK2 subunits are able to
associate with PfCK2 in vitro, all three subunits were ex-
pressed in E. coli as His- or GST-tagged proteins and used in
pull-down experiments. Mixtures of His- and GST-tagged pro-
teins were prepared, from which proteins were pulled down
using glutathione beads. The pulled-down proteins were then
subjected to Western blot analysis using an anti-His antibody
to detect any bound His-tagged protein that was copurified
with the GST-tagged proteins. PfCK2-His was copurified with
both GST-tagged beta subunits but not with GST alone (Fig.
5A). The interaction does not significantly alter the Km for
ATP (Fig. 5B) or the phosphorylation of calmodulin or the
peptide RRRSDDSDDDDD (data not shown). However, the
interaction of the beta subunits with the kinase has functional
significance, at least in vitro, since the activity of the kinase
toward -casein is reduced with increasing amounts of GST-
PfCK2 present in the reaction mixtures (Fig. 5C).
PfCK2 is essential for completion of the erythrocytic asex-
ual cycle. We next wanted to determine whether PfCK2 plays
essential functions in parasite survival. To generate a plasmid
able to disrupt the PfCK2 gene, an internal fragment of the
coding sequence, excluding the critical motifs Gly-X-Gly-X-X-
Ser (subdomain I, involved in anchoring of the ATP molecule)
and Gly-Pro-Glu (subdomain VIII, required for structural sta-
bility of the C-terminal lobe) (see Fig. S1 in the supplemental
material), was amplified and cloned into the transfection vec-
tor pCAM-BSD (47), which confers resistance to blasticidin.
Integration of this construct (pCAM-BSD-KOPfCK2a) into
the genomic locus by single-crossover homologous recombina-
tion is expected to result in a pseudodiploid configuration,
where both truncated copies will be unable to express a functional
enzyme, since both will lack one of the essential motifs (Fig. 6A).
After two independent transfections of pCAM-BSD-
KOPfCK2a into 3D7 parasites, integration was monitored in
the blasticidin-resistant populations by PCR (Fig. 6B), using
FIG. 5. PfCK2 and PfCK2 subunits interact in vitro. (A) Pull-down assays. Each of the GST-tagged subunits (indicated at the bottom of each
panel) was incubated with PfCK2-His (lane 1) or His-shPfCK22 (lane 2). Complexes containing the GST-tagged subunits were then purified
using glutathione agarose beads, and any bound His-tagged subunits were detected by Western blot analysis. Top, anti-His Western blots. Bottom,
Coomassie blue-stained gels. (B) The PfCK2 Km for ATP is not greatly altered in the presence of the PfCK2 subunits. ATP concentrations of
100 M, 50 M, and 25 M were used. Reaction mixtures contained PfCK2 alone or with equimolar amounts of PfCK21 or shPfCK22.
(C) Phosphorylation of -casein by PfCK2His in the presence of increasing concentrations of GST-tagged PfCK2 subunits (and concomitant
decreases in the concentration of GST) was quantified by phosphorimaging. Standard kinase assays were performed with 1 g of -casein, 1 g
of PfCK2His, and 6 g of GST/GST-PfCK2 in various proportions. The graph represents the combined results of three experiments (means and
standard deviations shown).
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primer combinations that allow discrimination between the
episome, the wild-type locus, and the disrupted locus. Only the
episome and the wild-type locus were detectable, with no sign
of integration even after prolonged culturing (16 weeks); in
contrast, we regularly observe disruption of nonessential genes
6 to 7 weeks posttransfection (for an example, see reference
42). This might be due either to the fact that the presence of an
intact PfCK2 gene is crucial for parasite asexual multiplica-
tion or to the possible nonrecombinogenicity of the locus. To
verify that the PfCK2 locus is indeed recombinogenic, we
proceeded to transfect wild-type parasites with a “3-tagging”
construct whose integration was expected not to cause loss of
function of the target protein. We readily observed integration
of the tagging construct (Fig. 7A to E) and size increase in the
PfCK2 protein caused by the HA tag (1.1 kDa) (Fig. 7F). This
demonstrates that the locus is accessible to recombination if no
loss of function is incurred, as is presumably the case with HA
tagging, and therefore strengthens the case that PfCK2 is
essential for the parasite’s asexual cycle.
We nevertheless wanted to ascertain that PfCK2 can be
disrupted if the enzyme is provided through expression of an
extraneous copy of the gene. To this effect, a complementation
plasmid was constructed, containing the full-length PfCK2
coding region under the control of the Pfhsp86 promoter and
preceding a 3 untranslated region (namely, the Plasmodium
berghei dihydrofolate reductase terminator sequence). The P.
falciparum hsp86 gene (PF07_0029) displays a similar mRNA
expression profile to the PfCK2 gene (28); therefore, its pro-
moter is presumably appropriate to drive expression of the
complementing protein. In parallel with the transfection of the
pCAM-BSD-KOPfCK2a plasmid alone, further populations
of parasites were cotransfected with both pCAM-BSD-
KOPfCK2a and the complementation plasmid. PCR analysis
(Fig. 6B, right) showed that disruption of the targeted locus
occurred only in the doubly transfected, doubly resistant par-
asites. Southern blot analysis independently confirmed that
integration occurred only in the doubly transfected parasites
(Fig. 6C). The 13-kb band that represents the wild-type locus
dramatically decreased in the doubly transfected parasites and
was undetectable in two clonal lines (E7 and G9) that were
derived from this culture by limiting dilution. There are mul-
tiple possibilities for the recombination of the KO and comple-
mentation plasmids with each other before or after integration,
which could account for the additional bands of unexpected
size observed (6 kb and 14 kb). The most important observa-
tion is that the wild-type band disappears only in the doubly
transfected parasites.
Taken together, these data provide strong evidence that
PfCK2 is essential to viability of the asexual erythrocytic stage
parasites.
PfCK2 kinase activity is amenable to inhibition. Using a
kinase-directed inhibitor library, we conducted a screen for
compounds that inhibit PfCK2. This screen identified the
compounds Rottlerin and ML-7 as inhibitors of PfCK2. The
IC50s of these compounds were determined for both PfCK2
and HsCK2 (Fig. 8). While ML-7 inhibits both enzymes with
an IC50 of roughly 3 to 4 M, Rottlerin exhibits differential
effects on the orthologues, inhibiting PfCK2 with an IC50 of 7
M and HsCK2 with an IC50 of 20 M. This result indi-
cates that differential inhibition is possible, despite the high
percent identity (65%) between the CK2 amino acid se-
quences of P. falciparum and Homo sapiens.
DISCUSSION
We have characterized a P. falciparum CK2 orthologue and
confirmed that the recombinant enzyme exhibits kinase activity
in vitro and exhibits features in common with other CK2
enzymes. PfCK2 contains the major motifs conserved across
FIG. 6. PfCK2 is necessary for erythrocytic-stage parasite viabil-
ity. 3D7 parasites transfected with pCAM-BSD-KOPfCK2a with or
without pCHD-PfCK2a were analyzed by PCR and Southern blotting.
(A) Disruption strategy for PfCK2. The locations of the primers used
for PCR screening and the HindIII sites used in Southern blotting are
shown. (B) PCR screening of genomic DNA (gDNA) from untrans-
fected 3D7 parasites, two separate pCAM-BSD-KOPfCK2a-trans-
fected lines (KOCK2a 1 and KOCK2a 2), and parasites transfected
with both the KO plasmid and the complementation plasmid
(KOCK2a  complement). Lane 1, amplification of the wild-type
PfCK2 locus (primers 1 and 2A; expected size, 1,030 bp). Lane 2,
amplification over the 5 integration boundary (primers 1 and 4; ex-
pected size, 677 bp). Lane 3, amplification over the 3 integration
boundary (primers 2B and 3; expected size, 1,060 bp). Lane 4, ampli-
fication of the insert in the pCAM-BSD-KOPfCK2a plasmid (primers
3 and 4; expected size, 610 bp). Evidence of integration is seen only in
gDNA from the doubly transfected parasite culture (KOCK2a  com-
plement). (C) This parasite line was cloned by limiting dilution, and
the gDNA was analyzed by Southern blotting. The restriction enzyme
HindIII was used to digest the gDNA, and the fragments were ana-
lyzed by Southern blotting using BSD and PfCK2 as probes. Lanes: 1,
untransfected 3D7; 2, KOCK2a1; 3, KOCK2a2; 4, KOCK2a plus com-
plement; 5, KOCK2a plus complement clone E7; anf 6, KOCK2a plus
complement clone G9.
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CK2 catalytic subunits, phosphorylates acidic sequences, inter-
acts with the putative PfCK2 subunits and the HsCK2 sub-
unit, is inhibited by the classic CK2 inhibitor TBB (3,4,5,6-
tetrabromobenzotriazole), with a similar IC50 to that of
HsCK2, and is able to utilize GTP or ATP as a cosubstrate.
We have also confirmed the identity of two PfCK2 subunits.
The N-terminal extension of PfCK22 is unusually long for
CK2 proteins, with 160 amino acids before the first conserved
residue (Trp161 in PfCK22). Most CK2 subunits from ver-
tebrates have only eight amino acids prior to this conserved
residue (Homo sapiens, Gallus gallus, Mus musculus, Xenopus
tropicalis, Bos taurus, and Danio rerio); this N-terminal exten-
sion is expanded in yeast (Saccharomyces cerevisiae, 37 resi-
dues), trypanosomatids (Trypanosoma brucei, 27 residues;
Leishmania major, 21 residues), plants (Arabidopsis thaliana,
100 residues; Oryza sativa, 92 residues), and alveolates (Cryp-
tosporidium parvum, 27 residues; Theileria parva, 34 residues).
Within the alveolates, Plasmodium yoelii yoelii (125 residues)
and Plasmodium vivax (157 residues) also have long extensions,
but the extension of P. falciparum is the longest known. Homo-
repeat-containing proteins make up 35.7% of the proteome of
P. falciparum, although the majority of these homorepeats are
asparagines and lysines (48), unlike the polymers of acidic
residues present in PfCK22. One hypothesis for the function
of this extension is the downregulation of the alpha subunit.
Polyglutamate is a potent CK2 inhibitor (50), and the N-ter-
minal extension of PfCK22 is rich in polyglutamate and pol-
yaspartate. This beta subunit also possesses an insertion of
extra acidic residues (including a stretch of 11 consecutive
aspartates) (Fig. 1) in the acidic domain known to downregu-
late CK2 (32). We have not been able to purify PfCK22 with
the N-terminal extension, and therefore this hypothesis re-
mains to be tested. However, we showed that the presence of
either beta subunit reduces the activity of PfCK2 toward
FIG. 7. PfCK2 can be targeted for recombination. (A) PCR screening for integration in genomic DNA (gDNA) from parasites transfected
with pCAM-BSD-HA-PfCK2a revealed the presence of parasites in which integration events had occurred. Lane 1, amplification of the wild-type
locus (primers 1 and 2; expected size, 1,176 bp). Lane 2, amplification over the 5 integration boundary (primers 1 and 4; expected size, 1,973 bp).
Lane 3, amplification over the 3 integration boundary (primers 2 and 3; expected size, 810 bp). Lane 4, amplification of the insert in the
pCAM-BSD-KOPfCK2a plasmid (primers 3 and 4; expected size, 610 bp). This culture still contained the wild-type locus, and therefore clonal lines
were derived from the culture by limiting dilution. (B) PCR screening for integration in gDNA from one of the parasite clones revealed that the
wild-type band had been lost (lane 1, 1,176 bp) and only the integration bands were seen. (D) This clonal line was further analyzed by Southern
blotting. (C) A schematic of the chromosomal gene locus, the pCAM-BSD-HA-PfCK2a plasmid, and the recombined locus, showing the locations
of oligonucleotide primers used for the PCR screens (A and B). Oligonucleotide identities are listed in Table S1 in the supplemental material.
HindIII sites and the expected sizes of the fragments of gDNA after restriction digestion are shown. (D) Southern blotting. Lanes: 1, untransfected
3D7 parasites; 2, PfCK2HA clone B3; and 3, PfCK2HA clone E1. (E) Western blot analysis showing PfCK2 expression in erythrocytic stage
parasites. Protein extract from unsynchronized erythrocytic-stage P. falciparum parasites was prepared from wild-type 3D7 parasites (lane 2) and
from parasites with a sequence encoding a HA tag incorporated at the 3 end of the PfCK2 gene locus (lane 3, clone B3; lane 4, clone E1). Protein
extract from unparasitized red blood cells (lane 1) and recombinant GST-PfCK2 (lane 5) were included as negative and positive controls. Two
identical Western blot analyses were performed with immunopurified rabbit anti-PfCK2 antibodies (right) or with preimmune serum from the
same rabbit as a negative control (left). The expected sizes of the proteins are indicated with arrows.
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-casein; such modulation of activity has been seen for other
CK2s, often in a substrate-dependent fashion, For example,
CK2 stimulates human CK2 activity toward topoisomerase II
and p53 and inhibits activity toward calmodulin (6). Thus, the
presence of two beta subunit species in P. falciparum (whereas
there is only one in human cells) is likely to allow exquisite
control of the activity of the catalytic subunit. The interactions
we detected in vitro between the recombinant catalytic and
regulatory subunits suggest that the P. falciparum CK2 subunits
may form a similar holoenzyme structure to that seen in other
organisms, although the stoichiometry of the complex in vivo
will require detailed analysis of parasite extracts in nondena-
turing conditions.
The existence of a number of discrete subpopulations of
mammalian CK2 associated with different cellular compart-
ments has been recognized (36), and it has been proposed that
this is mediated by assembly of CK2 subunits as well as inter-
action with many other proteins. Our observation that the
alpha and beta subunits possess putative signals for nuclear
localization and protein export, respectively, suggests that in
Plasmodium spp., like in other eukaryotes, CK2 may localize to
a variety of compartments. Work is in progress to address this
issue.
CK2 has been shown to be essential for life for a variety of
organisms (24, 31, 37). We have demonstrated here that
PfCK2 is required for parasite viability. We show that para-
sites lacking the enzyme are unable to survive or are impaired
in their growth rate to such an extent that they are outcom-
peted by the parasites which retain wild-type genes. Our ap-
proach allows us to conclude that PfCK2 plays an important
role during erythrocytic schizogony but does not provide any
information about the molecular basis for essentiality. We are
addressing this issue in a number of ways, including conditional
expression based on a destabilization domain (4), localization
(see above), and identification of interacting partners. Never-
theless, our data validate PfCK2 as a potential drug target. We
have also demonstrated that PfCK2 is amenable to inhibition
assays. Active HsCK2 is present in erythrocytes (53); this
raises the question of selectivity of antimalarial inhibitors
based on PfCK2 inhibition. We demonstrated that a small
molecule inhibitor, Rottlerin, has a much lower IC50 for
PfCK2 than for HsCK2. Although we have identified in
Rottlerin a compound that can distinguish between the human
and plasmodial CK2 enzymes, it is unlikely to represent a
suitable starting point for antimalarial drug discovery, since
Rottlerin has multiple targets (41) and is too weak and non-
specific an inhibitor even to be used in cellular assays (5).
However, we have established that differential inhibition is
possible, despite the 65% identity between the primary se-
quences of PfCK2 and HsCK2, which suggests that specific
inhibition of the plasmodial (versus host) enzyme should be
feasible. The level of activity of recombinant PfCK2 is such
that the development of a high-throughput assay should be
possible, opening the way for screening of chemical libraries as
a first step toward antimalarial drug discovery based on
PfCK2 inhibition.
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FIG. 8. PfCK2 can be distinguished from HsCK2 by small mol-
ecule inhibitors. Two small molecules, ML-7 and Rottlerin, were iden-
tified in a primary screen as inhibiting the activity of PfCK2 to below
10% of the uninhibited enzyme. The inhibitors Rottlerin and ML-7
were included in increasing concentrations in kinase assays with 25 M
ATP, 36 ng of enzyme, and the peptide RRREDEESDDEE as sub-
strate. Activity was measured using the phosphocellulose assay
method, and results were scored as a percentage of the control (no
inhibitor). (A) ML-7. (B) Rottlerin. Mean values from two experi-
ments are shown, with the error bars representing the standard devi-
ations. (C) The classical CK2 inhibitor, TBB, has a similar inhibitory
profile for PfCK2 and HsCK2.
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